13G Filing: Sabby Capital Opens Large Position in Rexahn Pharmaceuticals, Inc. (RNN)

Page 1 of 8
Hal Mintz‘s Sabby Capital has revealed a new position in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) through a 13G filing with the SEC. The position comprises 15.63 million shares and accounts for 7.33% of the company’s shares. There were just two shareholders of Rexahn as of December 31 among the investors that we track, those being Jim Simons’ Renaissance Technologies and Ken Griffin’s Citadel Investment. You can see the details of the new filing in the table below and can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Sabby Healthcare Master Fund, Ltd 0 10,425,000 0 10,425,000 10,425,000 4.89%
Sabby Volatility Warrant Master Fund, Ltd 0 5,200,000 0 5,200,000 5,200,000 2.44%
Sabby Management 0 15,625,000 0 15,625,000 15,625,000 7.33%
Hal Mintz 0 15,625,000 0 15,625,000 15,625,000 7.33%

Follow Hal Mintz's Sabby Capital

Page 1 of 98 SEC Filing



Under the Securities Exchange Act of 1934
(Amendment No.)*

Rexahn Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

761640 10 1
(CUSIP Number)

February 26, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
761640 10 1

Follow Ocuphire Pharma Inc. (NYSEMKT:OCUP)

Page 1 of 8